



Navigating Global Alternatives

www.57stars.com

DEAL ANNOUNCEMENT | Global Opportunity Fund 5

57 Stars Invests in Biofourmis Holdings Pte.

57 Stars LLC, an independent global alternative investment firm focusing particularly on high-growth sectors frequently driven by technological innovation, is pleased to announce its investment in **Biofourmis Holdings Pte.** (“Biofourmis”). The investment was made by 57 Stars’ **Global Opportunity Fund 5** (“GOF 5”), in the fifth generation of the firm’s global private equity investment vehicles, which has an emphasis on disruptive technologies in emerging markets. The investment was made alongside Openspace Ventures, a leading Southeast Asia venture capital firm.

“Digital therapeutics represent an extraordinary global growth opportunity in the healthcare sector, the adoption of which has been accelerated by COVID-19,” said John Engel, Managing Director at 57 Stars. “Biofourmis is uniquely positioned to leverage its AI platform to drive improved patient outcomes while also lowering provider costs, thus addressing critical health needs in markets with limited healthcare services available.” Cheng Chee Mun, 57 Stars Managing Director noted: “Biofourmis is a great example of global innovation providing cutting edge healthcare solutions across borders. This fast-growing digital therapeutics platform has developed a compelling franchise in cardiovascular health, and is well positioned to create innovative solutions targeting other chronic diseases. 57 Stars’ experience in the healthcare sector and our broad network of relationships have put us in a differentiated position to invest in highly impactful opportunities like Biofourmis, which accelerate progress toward universal health coverage, thus meeting U.N. Sustainable Development Goals while still targeting compelling returns for our investors.”

About Biofourmis Holdings Pte.

Biofourmis — a fast-growing global leader in digital therapeutics that powers personalized predictive care — discovers, develops, and delivers clinically validated software-based therapeutics to provide better outcomes for patients, advanced tools for clinicians to deliver personalized care, technology to demonstrate the value of and to complement pharmacotherapy, and cost-effective solutions for payers. Biofourmis has built Biovitals®, a highly sophisticated personalized AI-powered health analytics platform that predicts clinical exacerbation in advance of a critical event, which is the

backbone of its digital product pipeline across multiple therapeutic areas—including heart failure, oncology, infectious disease (e.g., COVID-19), chronic pain, acute coronary syndrome, and COPD. Biofourmis demonstrates the large-scale impact that innovation in healthcare technology can have on underserved populations around the world, providing them with access to high-quality, personalized care services that address basic health needs. The company's at-home remote monitoring solutions have been particularly powerful in driving improved healthcare outcomes during the COVID-19 pandemic, helping to reduce strain on hospital systems and lowering exposure risk while providing seamless integrated care.

About Global Opportunity Fund 5

57 Stars' GOF 5 is the firm's fifth generation flagship investment vehicle. It is a sector-focused, thematic investment fund committing to partnerships, secondaries, co-investments, and structured transactions globally. Targeting high-growth sectors, the fund particularly seeks opportunities to benefit from the innovation revolution in tech-enabled consumer businesses, health and care-related technologies, tech-enabled enterprises, mobility, and fintech/financial services.

About 57 Stars LLC

57 Stars is a globally focused, independent alternative investment manager with more than USD 4 billion in commitments raised and managed, and approximately two dozen professionals in six locations across the globe. Founded in 2005, the firm seeks to generate superior risk-adjusted returns by investing in high growth sectors of the global economy particularly those driven by secular tailwinds, disruptive forces, and technological innovation, adaption, and adoption. 57 Stars executes its investment strategy within a sustainable development framework.

LEARN MORE: www.57stars.com